Invivyd (IVVD) Cost of Revenue (2024 - 2025)
Invivyd (IVVD) posted Cost of Revenue of $1.1 million for Q4 2025, up 4.78% on a QoQ basis from $1.1 million in Q3 2025, and up 57.46% year-over-year from $724000.0 in Q4 2024.
Invivyd (IVVD) Cost of Revenue (2024 - 2025) Analysis & Trends
Invivyd's Cost of Revenue history runs 2 years deep, the most recent figure standing at $1.1 million for Q4 2025.
- Quarterly Cost of Revenue rose 57.46% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.7 million (up 131.58% YoY) and the FY2025 annual result came in at $3.7 million, up 131.58% from the prior year.
- Cost of Revenue was $1.1 million for Q4 2025 at Invivyd, up from $1.1 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $1.1 million in Q4 2025 and bottomed at $88000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.14 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 685,000.00 |
| Jun 30, 2025 | 685,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Mar 31, 2025 | 834,000.00 |
| Dec 31, 2024 | 724,000.00 |
| Dec 31, 2024 | 724,000.00 |
| Sep 30, 2024 | 806,000.00 |
| Sep 30, 2024 | 806,000.00 |
| Jun 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 88,000.00 |